HDAC9 and cancer: Although treatments involving combinations of docetaxel and sirtuin inhibitors have not been reported, combinations of docetaxel and other HDAC inhibitors such as trichostatin A and suberoylanilide hydroxamic acid (SAHA) have been reported to have synergistic effects related to caspase activation or tubulin acetylation in several cancer cell lines [48]–[50].